Halozyme (HALO) announced that Bristol Myers Squibb (BMY) received FDA approval for Opdivo Qvantig co-formulated with Halozyme’s Enhanze drug delivery technology for subcutaneous use in most previously approved adult, solid tumor intravenous Opdivo indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy combination therapy, or in combination with chemotherapy or cabozantinib.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Amazon invests $4B more in Anthropic, Gap reports Q3 beat: Morning Buzz
- Evotec takes notice of Halozyme withdrawal, convicted in standalone strategy
- Evotec falls 21% to $4.20 after Halozyme withdraws acquisition proposal
- Halozyme withdraws proposal to acquire Evotec
- Halozyme withdraws proposal to acquire Evotec for EUR 11.00 per share in cash